CNS effects of 1-isopropylamino-3-(4-indanoxy)-2-propanol hydrochloride (USVC-6524).
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D000605:Amino Alcohols / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D002389:Catatonia / Q000188:drug therapy*; D002490:Central Nervous System / Q000187:drug effects*; D004987:Ethers / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007192:Indenes / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D009132:Muscles / Q000187:drug effects*; D010830:Physostigmine / Q000633:toxicity; D011437:Propylamines / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D012640:Seizures / Q000188:drug therapy*; D012890:Sleep / Q000187:drug effects*; D014202:Tremor / Q000188:drug therapy
D000319:Adrenergic beta-Antagonists; D000605:Amino Alcohols; D004987:Ethers; D007192:Indenes; D011437:Propylamines; D010830:Physostigmine